RecruitingNCT04580134
Clozapine and risperidone in schizophrenia biotype 1
About this title
Read the official source — NCT04580134Medication studyAges 18–60United States
Understand this study
Who could participate?
Listed age limits: 18 years to 60 years.
- Listed locations
- Hartford and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 1, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 524
- Sponsor
- University of Texas Southwestern Medical Center
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT04580134
- Official title
Show the full official title
Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (Clozapine)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Hartford · Athens · Chicago
2 more locations
- Boston
- Dallas
Questions about this study
Who is behind this study?
The study sponsor is University of Texas Southwestern Medical Center, a university.
Does this study involve medication?
Yes. The study involves medication, including clozapine and risperidone.
Who can participate?
Listed age limits: 18 years to 60 years.
Is this study still recruiting?
The registry lists this study as recruiting.
